Back

The role of statins in patients with heart failure with preserved, mid-range and reduced ejection fraction; a meta-analysis and systematic review

26 August 2018 (17:30 - 17:45)
Organised by:
Congress Presentation Part of: Heart failure with mid-range ejection fraction: the controversy continues Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Agata Magdalena Bielecka-Dabrowa

Medical University of Lodz, Lodz (Poland)

3 More presentations in this session

Presentation thumbnail
Predictive value of diastolic dysfunction severity on long-term survival in heart failure patients with mid-range or reduced left ventricular ejection fraction
Doctor K. Hu (Wuerzburg, DE)
Abstract Slides Video
Presentation thumbnail
Functional behavior of heart failure with mid-range ejection fraction assessed by stress echocardiography and cardiopulmonary exercise test: truly distinctive phenotype o simply mid-way entity?
Doctor M. Barletta (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? - from the ESC-HF Long-Term Registry
Doctor A. Kaplon Cieslicka (Warsaw, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure with mid-range ejection fraction: the controversy continues

The Event

Event poster

ESC Congress 2018

26 August 2018 17:30 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources